- Home
- BELFA vs PVLA Comparison
BELFA vs PVLA Comparison
Compare BELFA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BELFA | PVLA |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | 4964 | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BELFA | PVLA |
|---|---|---|
| Price | $193.19 | $117.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $162.06 |
| AVG Volume (30 Days) | 53.7K | ★ 303.0K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $7.85 | N/A |
| P/E Ratio | $40.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.95 | $18.23 |
| 52 Week High | $227.42 | $151.18 |
Technical Indicators
Market Signals| Indicator | BELFA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 50.44 |
| Support Level | $114.22 | $85.53 |
| Resistance Level | $227.42 | $147.47 |
| Average True Range (ATR) | 8.94 | 7.72 |
| MACD | 1.53 | -2.76 |
| Stochastic Oscillator | 62.13 | 24.11 |
Price Performance
Historical ComparisonAbout BELFA Bel Fuse Inc.
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.